#USA #New York #Gross Law Firm #Ultragenyx #RARE

RARE Shareholder Alert: Legal Action Against Ultragenyx Pharmaceutical Inc.

On March 24, 2026, The Gross Law Firm issued a crucial notification to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). This alert targets investors who acquired shares during a specific class period, prompting them to consider leading a class action lawsuit in response to significant financial losses.

Summary of the Class Period

Registered shareholders who purchased shares between August 3, 2023, and December 26, 2025, are encouraged to connect with the law firm concerning their potential role as lead plaintiffs. However, it's critical to note that being appointed as a lead plaintiff is not necessary to participate in any possible recovery from the lawsuit.

Allegations Against Ultragenyx

This class action centers around allegations that Ultragenyx’s leadership made overly positive announcements regarding the potential of their drug setrusumab while simultaneously obscuring crucial negative information. Reports suggest that the management concealed detrimental facts about the drug's trial outcomes, which ultimately resulted in investors being misled.

Key Points of Concern

The tensions escalated when Ultragenyx publicly acknowledged on December 29, 2025, that their Phase III Orbit and Cosmic trials had failed to meet essential statistical significance benchmarks. The primary goal of these trials was to demonstrate a reduction in annualized clinical fracture rates, but the lack of significant findings led to sharp stock price declines. Notably, the stock plummeted from $34.19 per share on December 26, 2025, to $19.72 per share two days later, translating to a staggering 42.32% drop in value in a mere 48 hours.

Registration and Next Steps for Shareholders

The deadline for existing shareholders to register and potentially lead the lawsuit is April 6, 2026. To facilitate ongoing updates and ensure transparency throughout the litigation process, enrolled shareholders will gain access to a portfolio monitoring system to keep them informed about case progress. Registering for the class action bears no financial obligation or costs for the shareholders involved.

Why Choose The Gross Law Firm?

The Gross Law Firm boasts a national reputation for championing the rights of investors who have faced losses due to fraudulent or deceitful business practices. They are dedicated to pursuing justice for investors while promoting responsible corporate accountability. Their commitment extends to recovering losses incurred due to misleading information disseminated by companies like Ultragenyx.

Contact Information

For shareholders interested in gaining further details or joining the class action, The Gross Law Firm can be reached at their New York office:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

This lawsuit reflects a significant moment for Ultragenyx shareholders, as investors seek redress for the losses stemming from potentially misleading governance. The Gross Law Firm is prepared to assist those affected and ensure their voices are heard in the pursuit of justice.

• ---